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1. Introduction
  Myocardial ischemia-reperfusion injury often occurs 
after acute myocardial infarction thrombolysis, PTCA and 
coronary artery bypass grafting or other treatments. The 
mechanism of the injury is a patho-physiology phenomena 
caused by the expression of cytokines, especially the 
surface adhesion molecules[1], which can start and induce 
the aggregation and adhesion of inflammatory cells and 
cause immune injury of tissue cell. It seriously affects the 
treatment efficacy and prognosis of patients with myocardial 
infarction. Peroxisome proliferators-activated receptor 
(PPAR) is a member of nuclear receptor superfamily. 
Retinoic acid, degenerate prime, thyroid hormone, vitamin 
D, and orphan receptors are also members of the nuclear 
receptor superfamily[2]. PPAR毭 is mainly expressed in 
adipose tissues and the immune system, which closely 
related to the adipocyte differentiation, insulin resistance 
and body immune[3].
  Through activating nuclear receptors PPAR毭, rosiglitazone 
can regulate the production and transportation of the 
glucose, and also regulate the transcription of the insulin 
response genes. And rosiglitazone can relieve ischemia-
reperfusion myocardial injury by some physiological 
effects such as inhibiting the inflammation, improving the 
endothelial function and reducing the oxidative stress[4,5]. 
In this study we investigated the protective effect of 
rosiglitazone on myocardial ischemia-reperfusion injury 
and its mechanism. We expect to provide new ideas for the 
clinical treatment of myocardial ischemia-reperfusion, thus 
more patients can be benefit from it.
Objective: To explore mechanism and protective effect of rosiglitazone on myocardial ischemia 
reperfusion (I/R) injury. Methods: A total of 48 male Japanese white big-ear rabbits were 
randomly divided into control group (A), I/R group(B), low dose of rosiglitazone group (C), high 
dose of rosiglitazone group (D). Plasma concentration of and also reduced the concentration of 
plasma serum creatine kinase (CK), CK-MB, high-sensitivity C-reactive protein (hsCRP), ultra-
superoxide dismutase (SOD), malondialdehyde (MDA), lactic acid glutathione skin peroxidase 
(GSH-PX), nitric oxide (NO) and endothelin(ET) were measured 1 h later after I/R. Twenty-four 
hours after I/R the hearts were harvested for pathological and ultrastructural analysis.  Area of 
myocardial infarction were tested. Results: Plasma concentration of CK, CK-MB, hsCRP, NO, 
MDA and ET were decreased in C, D group compared with group B. Plasma concentration of T-SOD 
and GSH-Px were increased significantly in C, D group compared with group B. Compared with 
group B, pathological and ultrastructural changes in C and D group were slightly. There was 
significant difference in myocardial infarction area between group C, D and group B (P<0.05). 
Myocardial infarction area and arrhythmia rate were lower in group C, D compare with group B. 
Conclusions: Rosiglitazone may protect myocardium from I/R injury by enhancing T-SOD and 
GSH-Px concentration, inhibit inflammatory reaction, and improve endothelial function. 
Xia-Qing Gao et al./Asian Pacific Journal of Tropical Medicine (2013)228-231 229
2. Materials and methods
2.1. Animal
  Male Japanese long-ear white rabbits, (2.50依0.25) kg, 
provided by medical experimental animal center of Liaoning 
Medical College. Permit number of experimental animals 
was SYXK (Liao) 20030019.
2.2. Medicines and reagent
  Rosiglitazone hydrochloride tablets were from the Shanghai 
First Biochemical Pharmaceutical Co., Ltd., batch number 
06080204. The tablets were temporary compound with saline, 
then stored for use after sterilization. Glucose injection was 
from Jinan Limin Pharmaceutical Co., Ltd., batch number 
0512547. Sodium chloride injection was from Shenyang 
Zhiying Pharmaceutical Factory, batch number 06080204. 
ultra-superoxide dismutase (SOD), malondialdehyde (MDA), 
lactic acid glutathione skin peroxidase (GSH-PX), nitric 
oxide (NO) and endothelin (ET) kit were all purchased from 
Nanjing Jiancheng Bioengineering Institute.
2.3. Instruments
  HITACHI 7170A automatic biochemical analyzer; 721 
visible spectrophotometer (Shanghai Precision & Scientific 
Instrument Co., Ltd.); Ultraviolet visible spectrophotometer 
type-UV300; K15-C low temperature ultracentrifuge 
(Beijing medical centrifuge factory); SHH. 7121.6OO electric 
constant temperature tris-use water tank (Beijing Yong-
Guangming medical equipment factory); Shimadzu LC-9A 
liquid chromatograph; Fluorescent detector type-RF535; IX-
70 inverted fluorescence microscope; The OLYMPUS optical 
microscope type-CH20; OLYMPUS microscope photography 
type-C35A; Image analyzer CIAS-1000; Electronic balance; 
Enzyme mark instrument MC-ASCENT; Electrophoresis 
apparatus (DYY-6C); Low temperature refrigerator and ultra 
low temperature refrigerator (MDFU40865); Animal ventilator 
(HX-200).
2.4. Establishment of myocardial ischemia-reperfusion injury 
models in rabbits
  Healthy male Japanese white big-ear rabbits were under 
anesthesia with urethane (20%, 1 g/kg). Animals were 
then bound to a plate with the back side down and chest 
shearing. A skin incision was made from the sternoclavicular 
joint line to the point above the xiphoid process along the 
sternum midline. The 2nd, 3rd, 4th ribs were cut in the left 
sternal margin, stretched with a thoracic incision, then the 
pericardium was opened to expose the heart. A small round 
looper stab 2 mm below the left bundel of coronary artery 
was hold by needle holder with the 2/T line for ligation.
2.5. Grouping and administration
  A total of 48 rabbits were randomly divided into four 
groups: (1) Sham operation group: Coronary artery was only 
exposed but not ligated. Rabbits were fed with common 
pellet feedstuff for 3 days; (2) Ischemia-reperfusion group: 
ligated for 30 min, under reperfusion for 60 min. The 
rabbits were feed with common pellet feedstuff for 3 days; 
(3) Low dose rosiglitazone group: ligated for 30 min, under 
reperfusion for 60 min. Rabbits were fed with common 
pellet feedstuff for 3 days and rosglitazone 0.5 mg/kg/day; 
(4) High dose rosiglitazone group: ligated for 30 min, under 
reperfusion for 60 min. Rabbits were fed with common 
pellet feedstuff for 3 days and rosglitazone 3 mg/kg/day. 
Successful ligation was confirmed by significantly ascending 
ST-segment of ECG in the ischemia-reperfusion group, low 
dose rosiglitazone group and high dose rosiglitazone group 
after operation. After reperfusion for 60 min, common carotid 
artery blood was added with heparin anticoagulant tube for 
biochemical testing.
2.6. Indexes measurement
  Plasmic level of myocardial enzymes plasma serum (CTn栺,
 CK-MB), high-sensitivity C-reactive protein (hsCRP) were 
measured in carotid arterial blood under anticoagulation. 
The blood was centrifuged at 2 500 rpm for 10mins, and then 
the supernatant was collected to determine plasma SOD, 
MDA, GSH-PX, NO and ET.
  The hearts were harvested, then were rinsed with PBS 
buffer. The ischemic area of the heart were cut into 
approximately 1 mm in parallel, and were placed in 1% TTC 
or 0.25% NBT phosphate buffer (pH=7.4), 37℃,under water 
bath for 30 min. The dyed and undyed areas were isolated 
under dissecting microscope. The infarcted myocardium 
was pale and the none-infarcted myocardium was blue. 
The BI2000 image analysis system was used to calculate the 
percentage of the infarcted myocardium area accounted for 
the total ventricular area.
  Isolated hearts were washed with stationary liquid. The left 
ventricular anterior myocardial tissues were cut into strips, 
and then placed in stationary liquid for 2 h, followed by 
rinsed with 0.09 mmol KH2PO4 for 15 min, and stored in this 
solution. It was dehydrated in ascending series of ethanol, 
cleared in xylene, embedded in paraffin, and stained by 
HE staining. Then the structural c myocardial pathological 
change was observed under light microscope.
2.7. Statistical analysis
  The experimental data were analyzed with SPSS17.0 
statistical software. All measurement data were expressed 
with mean依SD. And single-factor analysis of variance 
(ANOVA) was applied in the comparison among many groups, 
q-test was used to compare between two groups. P <0.05 
indicated statistical significance. Comparatively describing 
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method was used to analyze the pathomorphological data.
3. Results
3.1. Effect on cardiac enzymes (CTn栺, CK-MB) content and 
hsCRP content in plasma 
The results showed that compared with the sham group,the 
CTn栺, CK-MB, and hsCRP levels in plasma were 
significantly increased in the ischemia-reperfusion group. 
And compared with the ischemia-reperfusion group,the 
CTn栺, CK-MB, hsCRP levels in plasma in the high dose 
rosiglitazone group and the low-dose rosiglitazone group 
were decreased significantly (Table 1).  
Table 1
Effect on cardiac enzymes (CTn栺, CK-MB) content and hsCRP 
content (mean依SD).
Groups CTn栺 (毺g/mL) CK-MB (毺g/mL) hsCRP (U/L)
Group A 110.35依25.96 134.75依35.12 47.10依2.82
Group B 182.37依30.46△ 214.52依43.78△ 77.35依1.32△
Group C 136.42依28.37★ 157.21依45.91★ 53.38依1.56★
Group D 120.53依31.03★ 142.36依40.13★ 50.24依1.47★
Note: Compared with group B, ★P <0.01; compared with the sham 
group, △P <0.01.
3.2. Effect on NO, ET and GSH-Px content in plasma
  The results showed that compared with the sham group, 
the NO, GSH-Px levels in plasma were significantly 
decreased in the ischemia-reperfusion group, while ET 
levels increased. Compared with the ischemia-reperfusion 
group, the NO, ET, GSH-Px levels in plasma in the high dose 
rosiglitazone group and the low-dose rosiglitazone group 
were increased significantly, while ET levels decreased 
significantly. The content of NO, ET, GSH-Px in plasma had 
no significant difference between rosiglitazone high dose 
group and rosiglitazone low dose group (Table 2). 
 
Table 2
Effect on NO, ET, GSH-Px content in plasma after the myocardial 
ischemia and reperfusion injury (mean依SD).
Groups NO(毺g/mL) ET (pg/mL) GSH-Px (U0
Group A 71.28依4.32 40.23依6.35 218.23依21.75
Group B 32.51依5.25△ 297.57依7.58△ 112.42依31.58△
Group C 57.32依6.34★ ★ 143.56依6.54★ 176.56依33.81★ ★
Group D 65.84依5.05★   121.28依8.82★ 187.34依27.29★ ★
Note: compared with ischemia-reperfusion group, ★ ★ P <0.05, ★ P 
<0.01; compared with the sham group, △ P <0.01.
3.3. Effect on T-SOD and MDA content in plasma 
  The results showed that compared with the sham group, 
the MDA levels in plasma were significantly increased 
in the ischemia-reperfusion group, and the T-SOD was 
significantly decreased. Compared with the ischemia-
reperfusion group, the MDA levels in plasma in the high 
dose rosiglitazone group and the low-dose rosiglitazone 
group were decreased significantly, while the T-SOD was 
increased significantly (Table 3).  
Table 3
Effect on the T-SOD and MDA content in plasma (mean依SD).
Groups  T-SOD(U/L)   MDA(nmol/mL)
Group A 521.38依34.42 7.14依0.42
Group B 390.54依33.86△ 12.84依0.79△
Group C 454.58依25.43★ ★  8.10依0.54★ 
Group D 489.27依15.62★ ★  7.46依0.37★ 
Note: Compared with ischemia-reperfusion group ★ P <0.05, 
★ ★ P <0.01; compared with the sham group, △ P <0.05.
3.4. Myocardial infarct size
  As compared with sham-operated group [(19.2依5.5%)], the 
myocardial infarct size of the ischemia-reperfusion group 
[(41.3依8.5)%] was significantly increased (P <0.05). Compared 
with the ischemic reperfusion group, the myocardial infarct 
size of the low-dose rosiglitazone group [(26.5依7.1)%] 
and the high-dose rosiglitazone group [(23.4依6.6)%] were 
significantly decreased (P<0.05). Compared with the sham 
group, the rosiglitazone low-dose group and the rosiglitazone 
high-dose group showed no significant difference (P> 0. 05).
3.5. Pathological structures under light microscopy
  Myocardial fibers arranged in neat rows in the sham group 
under the light microscope, without inflammatory cell 
infiltration of the myocardial interstitial. Group I/R were 
of swelling and disorder myocardial fibers, inflammatory 
cells and even focal necrosis in the myocardial interstitial. 
Myocardial cell nuclei in high and low dose rosiglitazone 
groups were in uniform size, myocardial fibers were mild 
swelled, and there were fibroblasts and inflammatory cell 
infiltration at different degrees.
4. Discussion
  Acute myocardial infarction is the leading disease 
threatening the human life and health at present, while 
myocardial ischemia - reperfusion can cause irreversible 
damage,death and apoptosis to the damaged myocardial 
cells, thus aggravate myocardial damage and increase 
mortality[6]. Myocardial ischemia reperfusion injury is a 
process which was participated by a variety of inflammatory 
cell nucleus inflammatory cytokines. Neutrophils, 
monocytes, mast cells, and macrophages all play important 
roles in this process, while TNF-毩, IL-1, IL-6, IL-8 were 
also involved in the reperfusion injury[7].
  PPAR-毭 is expressed in many immune cells, and PPAR-
毭 ligand 15d-PGJ2 can regulate many immune responses. 
With the presence of PPAR-毭, 15d-PGJ2 at very low 
concentrations can inhibit the transcriptional effects which 
is mediated by LPS, active protein 21, NF-毷B, and the 
signal TRANSDUCER and activator of transcription 1[8]. With 
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the interactions with NF-毷B protein, PPAR-毭 can prevent 
the binding of NF-毷B with the inflammatory cytokines 
gene promoter region homologous cis element[9]. PPAR-毭 
plays an important role in regulating the differentiation of 
immune cells, such as mononuclear P macrophages, T cells 
and NK cells. By PPAR毭-dependent pathway, PPAR-毭 
ligands can inhibit T cells and NK cells produce IFN2毭[10]. 
Gene chip technology showed that the PPAR毭 expression 
in type 2 T cells is significantly stronger than in the 1-type T 
cells (approximately 5 to 8 times). In culture condition, type 
2 immune cells (added with IL-4 and IFN-毭 antibody) can 
induce the expression of PPAR-毭in NK cells. The activated 
PPAR-毭 can induce the production of NF-毩, IL-1, 
IL-2 and IL-6, which can inhibit monocyte inflammatory 
cytokines T[11,12] and produce the anti-inflammatory effect. 
The key to the activation of T lymphocyte is to control 
the early differentiation of IL-2 gene expression of the 
lymphocyte reaction. The activation of PPAR-毭 can inhibit 
the gene expression of IL-2, thus can inhibit the early 
activation of T lymphocytes and shows anti inflammatory 
effect.
  The experiment showed that the pretreatment of PPAR-毭 
receptor rosiglitazone on myocardial ischemia-reperfusion 
model can significantly increase the concentration of 
SOD, GSH-PX, NO, and also reduced the concentration 
of plasma serum CK-MB cTNI, hsCRP, MDA and ET. It 
can significantly reduce the incidence of arrhythmia and 
reduce the size of myocardial infarction. Rosiglitazone 
can protect myocardial mitochondrial function of rats and 
maintain mitochondrial ultrastructural integrity. From the 
results of the experiment we can speculate that rosiglitazone 
pretreatment can protect myocardial and reduce ischemia-
reperfusion injury. However, the specific mechanism is 
still unclear. Studies have shown that as PPAR-毭 receptor 
agonist, rosiglitazone can affect the formation and activation 
of inflammatory cells and inflammatory cytokines, inhibit 
the expression of MCP-1, intercellular adhesion molecule 
and inducible oxide synthase by regulating the expression 
of PPAR-毭[13,14]. In addition, Khandoudi et al[15] found that 
by inhibiting Jun N-terminal kinase phosphorylation and 
inhibit activated protein-1 DNA binding activity, TZDs can 
inhibit the damage of myocardial ischemia and improve the 
function of heart. Rosiglitazone can improve myocardial 
ischemia-reperfusion injury by inhibiting inflammation, 
improving endothelial function and reducing the generation 
of oxygen free radicals. The specific mechanism is the 
content of our further study.
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